When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …

With the increasing use of mycophenolic acid (MPA) in solid organ transplantation, the need
for more accurate drug dosing has become evident. Personalized immunosuppressive …

CHAIR: Costanzo MR: Midwest Heart Foundation, Lombard Illinois, USA TASK FORCE 1:
Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland …

Coronavirus Disease 2019 (COVID‐19) has become a pandemic since March 2020. We
describe here 2 cases of COVID‐19 infection in a posttransplant setting. First one is a 59 …

These guidelines cover the care of patients from the period following kidney transplantation
until the transplant is no longer working or the patient dies. During the early phase …

This review aims to provide an update of the literature on the pharmacology and toxicology
of mycophenolate in solid organ transplant recipients. Mycophenolate is now the …

Therapeutic drug monitoring (TDM) is a fundamental tool when administering drugs that
have a limited dosage or high toxicity, which could endanger the lives of patients. To carry …

Background Overimmunosuppression is a widely recognized risk factor for BK virus (BKV)
infection, particularly with the combination of tacrolimus, mycophenolate mofetil (MMF), and …

Although therapeutic drug monitoring (TDM) of immunosuppressive drugs has been an
integral part of routine clinical practice in solid organ transplantation for many years …

The immunosuppressive agent mycophenolate is used extensively in kidney transplantation,
yet dosing strategy applied varies markedly from fixed dosing (“one-dose-fits-all”), to …